Skip to main content

Table 1 Demographic data of 33 patients reported in the present study and the results of antimicrobial susceptibility testing for the associated 45 carbapenemase-producing Enterobacteriaceae (CPE) isolates

From: Genomic and clinical characterisation of multidrug-resistant carbapenemase-producing ST231 and ST16 Klebsiella pneumoniae isolates colonising patients at Siriraj hospital, Bangkok, Thailand from 2015 to 2017

  

Demographic data of patients

Characteristic of isolated bacteria

Antimicrobial susceptibility testing results

Patient No.

Age group

Ward

Treatment

Outcome

Hospital mortality

Strain ST

Taxonomy

Collection date

Type

MER

AMK

COL

FOS

1

E

IM

COL+FOS

Nonresponse

Death

KPCRETH01 (14)

K. pneumoniae

15/12/2015

Co

R

R

S

S

      

KPCRETH05 (14)

K. pneumoniae

22/12/2015

Co

R

R

S

S

2

E

ICU

COL+PIP

Nonresponse

Death

KPCRETH06 -

K. quasipneumoniae

01/04/2016

Co

R

R

S

R

      

ECCRETH01 (14)

K. pneumoniae

28/01/2016

Co

R

R

S

R

3

E

IM

No treatment

Not applicable

Alive

ECCRETH02 (410)

E. coli

21/12/2015

Co

R

R

S

S

4

E

IM

No treatment

Not applicable

Alive

KPCRETH07 (16)

K. pneumoniae

08/01/2016

Co

R

R

S

S

5

E

IM

No treatment

Not applicable

Alive

KPCRETH02 (16)

K. pneumoniae

01/09/2016

Co

R

I

S

R

6

E

IM

No treatment

Not applicable

Death

KPCRETH08 (70)

K. pneumoniae

17/02/2016

Co

R

R

S

I

      

KPCRETH09 (16)

K. pneumoniae

23/02/2016

Co

R

R

S

I

7

E

IM

No treatment

Not applicable

Death

KPCRETH10 (37)

K. pneumoniae

08/02/2016

Co

R

R

S

R

8

E

IM

No treatment

Not applicable

Death

KPCRETH11 (16)

K. pneumoniae

17/02/2016

Co

R

S

S

R

9

OA

ICU

COL+TIG

Superinfection

Alive

KPCRETH12 (16)

K. pneumoniae

08/04/2016

Co

R

R

S

R

10

OA

IM

No treatment

Not applicable

Alive

KPCRETH13 (16)

K. pneumoniae

26/04/2016

Co

R

I

S

S

11

YA

ICU

No treatment

Not applicable

Alive

KPCRETH14 (231)

K. pneumoniae

11/05/2016

Co

R

R

S

I

      

KPCRETH15 (231)

K. pneumoniae

27/05/2016

Co

R

R

S

I

12

E

ICU

No treatment

Not applicable

Alive

KPCRETH16 (231)

K. pneumoniae

17/05/2016

Co

R

R

S

R

13

E

ICU

No treatment

Not applicable

Death

ECCRETH03 (231)

K. pneumoniae

29/04/2016

Co

R

R

S

R

14

YA

IM

No treatment

Not applicable

Alive

ECCRETH04 (2003)

E. coli

18/08/2016

Co

R

R

S

S

      

ECCRETH05 (2003)

E. coli

26/08/2016

Co

R

R

S

S

15

E

IM

No treatment

Not applicable

Alive

ECCRETH06 (410)

E. coli

28/11/2016

Co

R

S

S

R

      

KPCRETH17 -

E. hormaechei

09/12/2016

Co

R

S

S

R

16

E

IM

COL+FOS

Response

Alive

KPCRETH03 (231)

K. pneumoniae

30/05/2016

Co

R

R

S

R

      

KPCRETH04 (231)

K. pneumoniae

21/06/2016

Co

R

R

S

R

      

KPCRETH26 (231)

K. pneumoniae

16/08/2016

Co

R

R

S

R

17

E

IM

COL+FOS

Response

Alive

KPCRETH18 (101)

K. pneumoniae

09/12/2015

In

R

R

S

I

      

KPCRETH19 (101)

K. pneumoniae

05/01/2016

In

R

R

S

I

      

KPCRETH20 (101)

K. pneumoniae

12/01/2016

In

R

R

S

I

18

E

ICU

COL+FOS

Nonresponse

Death

KPCRETH21 (231)

K. pneumoniae

24/03/2016

In

R

R

S

R

19

YA

ICU

COL+ERT

Response

Alive

KPCRETH22 (16)

K. pneumoniae

07/04/2016

In

R

S

S

I

      

KPCRETH23 (16)

K. pneumoniae

11/05/2016

In

R

S

S

I

      

KPCRETH24 (16)

K. pneumoniae

18/05/2016

In

R

S

S

I

20

OA

IM

COL

Response

Death

KPCRETH25 (16)

K. pneumoniae

27/05/2016

In

R

I

S

I

21

OA

IM

COL+MER

Response

Alive

KPCRETH27 (231)

K. pneumoniae

10/06/2016

In

R

R

S

R

22

YA

ICU

COL+PIP

Nonresponse

Death

KPCRETH28 (16)

K. pneumoniae

16/06/2016

In

R

I

S

R

23

YA

IM

COL+ FOS

Response

Alive

KPCRETH29 (14)

K. pneumoniae

22/06/2016

In

R

R

S

R

24

OA

IM

COL+PIP

Superinfection

Death

KPCRETH30 (14)

K. pneumoniae

17/05/2016

In

R

S

S

I

25

E

ICU

COL+ FOS

Superinfection

Death

KPCRETH31 (231)

K. pneumoniae

24/06/2016

In

R

R

S

I

26

E

IM

COL+ FOS

Response

Alive

KPCRETH32 (231)

K. pneumoniae

11/08/2016

In

R

R

S

R

27

OA

IM

COL+FOS

Superinfection

Death

KPCRETH33 (231)

K. pneumoniae

10/10/2016

In

R

S

S

R

28

OA

IM

COL+ FOS

Response

Alive

ECCRETH07 (231)

K. pneumoniae

15/12/2016

In

R

S

S

S

29

OA

IM

COL+FOS + GEN

Superinfection

Death

KPCTRPRTH01 (16)

K. pneumoniae

05/12/2016

In

R

R

R

R

30

OA

ICU

COL+ LEV

Superinfection

Death

KPCTRPRTH02 (231)

K. pneumoniae

03/01/2017

In

R

R

R

R

31

E

ICU

COL+FOS + GEN

Response

Alive

KPCTRPRTH03 (231)

K. pneumoniae

23/01/2017

In

R

R

R

R

32

OA

ICU

COL+MER

Superinfection

Death

KPCTRPRTH04 (16)

K. pneumoniae

17/04/2017

In

R

R

R

R

33

OA

ICU

COL+MER + LEV

Response

Alive

KPCTRPRTH05 (16)

K. pneumoniae

20/04/2017

In

R

R

R

R

  1. YA Young adult (18–39 years), OA Older adult (40–64 years), E Elderly (65+ years), IM Internal medicine ward, yrs. Years, ICU Intensive care unit, MER Meropenem, AMK Amikacin, COL Colistin, ERT Ertapenem, FOS Fosfomycin, PIP Piperacillin–tazobactam, TIG Tigecycline, GEN Gentamicin, LEV Levofloxacin, NR Nonresponse: worsening or persistence of clinical signs and/or symptoms of CPE infection, R Response: absence or improvement of all clinical signs and symptoms of CPE infection, SI Superinfection: second infection superimposed on an earlier one by different bacteria, Co Colonisation, In Infection, S Susceptible, I Intermediate, R Resistant